Display options
Cite
Rostami J, Jäntti M, Cui H, et al. Corrigendum to "Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells" [Biomed. Pharmacother. 131 (2020) 110788]. Biomed Pharmacother. 2020;133:111019doi: 10.1016/j.biopha.2020.111019.
Rostami, J., Jäntti, M., Cui, H., Rinne, M. K., Kukkonen, J. P., Falk, A., Erlandsson, A., & Myöhänen, T. (2021). Corrigendum to "Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells" [Biomed. Pharmacother. 131 (2020) 110788]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 133111019. https://doi.org/10.1016/j.biopha.2020.111019
Rostami, Jinar, et al. "Corrigendum to "Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells" [Biomed. Pharmacother. 131 (2020) 110788]." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 133 (2021): 111019. doi: https://doi.org/10.1016/j.biopha.2020.111019
Rostami J, Jäntti M, Cui H, Rinne MK, Kukkonen JP, Falk A, Erlandsson A, Myöhänen T. Corrigendum to "Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells" [Biomed. Pharmacother. 131 (2020) 110788]. Biomed Pharmacother. 2021 Jan;133:111019. doi: 10.1016/j.biopha.2020.111019. Epub 2020 Nov 24. PMID: 33246737.
Copy Download .nbib Format: NLM
Share it on

Biomed Pharmacother. 2021 Jan;133:111019. doi: 10.1016/j.biopha.2020.111019. Epub 2020 Nov 24.

Corrigendum to "Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells" [Biomed. Pharmacother. 131 (2020) 110788].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Jinar Rostami, Maria Jäntti, Hengjing Cui, Maiju K Rinne, Jyrki P Kukkonen, Anna Falk, Anna Erlandsson, Timo Myöhänen

Affiliations

  1. Molecular Geriatrics, Department of Public Health and Caring Sciences, Rudbeck Laboratory, Uppsala University, 751 85 Uppsala, Sweden.
  2. Division of Pharmacology and Pharmacotherapy/Drug Research Program, University of Helsinki, Viikinkaari 5E, P.O. Box 56, 00014, University of Helsinki, Finland.
  3. Division of Pharmaceutical Chemistry and Technology/Drug Research Program, Faculty of Pharmacy, P.O. Box 56, 00014, University of Helsinki, Finland.
  4. Department of Pharmacology, Institute of Biomedicine, Faculty of Medicine, P.O. Box 63, 00014, University of Helsinki, Finland.
  5. Department of Neuroscience, Karolinska Institutet, Stockholm 17177, Sweden.
  6. Division of Pharmacology and Pharmacotherapy/Drug Research Program, University of Helsinki, Viikinkaari 5E, P.O. Box 56, 00014, University of Helsinki, Finland; Integrative Physiology and Pharmacology Unit, Institute of Biomedicine, 20014 Turun yliopisto, University of Turku, Finland. Electronic address: [email protected].

PMID: 33246737 DOI: 10.1016/j.biopha.2020.111019

[No abstract available.]

Publication Types